HCC1569Homo sapiens (Human)Cancer cell line
Also known as: Hamon Cancer Center 1569, HCC-1569
Quick Overview
Human breast cancer cell line with PI3K pathway mutations and resistance to inhibitors.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1255 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Breast[UBERON:UBERON_0000310] |
Donor Information
| Age | 70 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Race | black_or_african_american |
| Subtype Features | basal_A HER2+ |
Disease Information
| Disease | Breast ductal carcinoma |
|---|---|
| Lineage | Breast |
| Subtype | Breast Invasive Ductal Carcinoma |
| OncoTree Code | IDC |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000930_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Glu294Ter (c.880G>T) | Unspecified | - | PubMed=12872257 |
| MutationSimple | PTEN | p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA) | Heterozygous | - | Unknown, Unknown, PubMed=25230021 |
| MutationSimple | FHIT | p.Val97Phe (c.289G>T) (651G>T) | Heterozygous | Germline | from parent cell line HCC1569 |
| MutationSimple | BRCA2 | p.Val1862fs*1 (c.5578delA) | Heterozygous | - | from parent cell line HCC1569 |
| MutationSimple | BRCA2 | p.Asn1100Thr (c.3299A>C) | Heterozygous | - | from parent cell line HCC1569 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Activating mutations in PIK3CB confer resistance to PI3K inhibition and define a novel oncogenic role for p110beta.
Hampton G.M., Lackner M.R.
Cancer Res. 76:1193-1203(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Modeling precision treatment of breast cancer.";
Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Genome Biol. 14:R110.1-R110.14(2013).
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
McCormick F., Gray J.W.
Cancer Cell 24:450-465(2013).
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Martens J.W.M.
Breast Cancer Res. 15:R33.1-R33.17(2013).
Molecular characterisation of cell line models for triple-negative breast cancers.
Reis-Filho J.S., Tutt A.
BMC Genomics 13:619.1-619.14(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Lung cancer cell lines as tools for biomedical discovery and research.
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
J. Natl. Cancer Inst. 102:1310-1321(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Pollack J.R.
PLoS ONE 4:E6146-E6146(2009).
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.
Petersen O.W., Gray J.W., Bissell M.J.
Mol. Oncol. 1:84-96(2007).
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
Cancer Cell 10:515-527(2006).
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Minna J.D.
Oncogene 20:1005-1009(2001).
Comparison of features of human breast cancer cell lines and their corresponding tumors.
Gazdar A.F.
Clin. Cancer Res. 4:2931-2938(1998).
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.
Tomlinson G.E., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., Shay J.W.
Int. J. Cancer 78:766-774(1998).
Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
Gazdar A.F.
Cancer Res. 57:3664-3668(1997).